```
=> d his

     (FILE 'HOME' ENTERED AT 14:55:16 ON 22 OCT 2004)

     FILE 'REGISTRY' ENTERED AT 14:55:30 ON 22 OCT 2004
L1                STRUCTURE UPLOADED
L2              1 S L1
L3             20 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:56:42 ON 22 OCT 2004
L4              4 S L3

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



=> d 1-4 bib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:802451 CAPLUS
TI Selective activation of cellular activities mediated through a common TOLL-like receptor
IN Fink, Jason R.; Gupta, Shalley K.
PA 3M Innovative Properties Company, USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004191833	A1	20040930	US 2004-807934	20040324
WO 2004087049	A2	20041014	WO 2004-US8979	20040324

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-457336P P 20030325
AB Methods of identifying compds. that selectively modulate cellular activities mediated by a common TLR are provided. Generally, the methods include providing an assay to detect modulation of a first cellular activity mediated by a TLR; providing an assay to detect modulation of a second cellular activity mediated by the TLR; performing each assay using a test compound; and identifying the test compound as a compound that selectively modulates at least one cellular activity of a plurality of activities mediated by a common TLR if the test compound modulates the first cellular activity to a different extent than it modulates the second TLR-mediated cellular activity. Compds. identified by such methods, pharmaceutical compns. including such compds., and methods of treating a condition by administering such pharmaceutical compns. to a subject are also provided.
IT **565454-55-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective activation of cellular activities mediated through common TOLL-like receptor)
RN 565454-55-9 CAPLUS
CN Methanesulfonamide, N-[2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:566606 CAPLUS
DN 141:123628
TI Preparation of aryl/heteroaryl substituted imidazoquinolines as immunomodulators
IN Hays, David S.; Niwas, Shri; Kshirsagar, Tushar; Ghosh, Tarun K.; Gupta, Shalley K.; Heppner, Philip D.; Merrill, Bryon A.; Bonk, Jason D.; Danielson, Michael E.; Gerster, John F.; Haraldson, Chad A.; Johannessen, Sarah C.; Kavanagh, Maureen A.; Lindstrom, Kyle J.; Prince, Ryan B.; Radmer, Matthew R.; Rice, Michael J.; Squire, David J.; Strong, Sarah A.;

Wurst, Joshua R.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 465 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058759	A1	20040715	WO 2003-US40373	20031218
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004147543	A1	20040729	US 2003-739787	20031218
PRAI US 2002-435889P	P	20021220		
US 2003-516331P	P	20031031		

OS MARPAT 141:123628
GI



I

AB Title compds. I (R = alkyl, alkoxy, OH, CF3; n = 0, 1; R1, R2 = H, non-interfering substituent; R3 = ArZ, aminosulfonylaryl, aminocarbonylaryl, etc.; Ar = aryl, heteroaryl; Z = bond, alkylene, alkenylene, alkynylene) which are immunomodulators, inducing cytokines biosynthesis, and inhibiting tumor necrosis factors biosynthesis, are prepared For example, 2-butyl-1-isobutyl-7-(thiophen-3-yl)-1H-imidazo[4,5-c]quinolin-4-amine was prepared in a multi-step synthesis starting from 3-bromoaniline, tri-Et orthoformate, and Meldrum's acid. I are useful in the treatment of viral and neoplastic diseases.

IT **723295-51-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoquinoline derivs. as immunomodulators for treatment of viral and antineoplastic diseases)

RN 723295-51-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-1-(3-methoxypropyl)-1H-imidazo[4,5-c]quinolin-7-yl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723266-02-2
CMF C24 H29 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:570648 CAPLUS
DN 139:133563
TI Preparation of sulfonamidoalkoxyalkylimidazoquinolines as immune response modulators.
IN Crooks, Stephen L.; Griesgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.; Roberts, Ralph R.; Wei, Ai-Ping
PA 3M Innovative Properties Co., USA
SO U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 12,599.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003139441	A1	20030724	US 2002-165443	20020607
	US 6677347	B2	20040113		
	US 2002193396	A1	20021219	US 2001-12599	20011206
	US 6683088	B2	20040127		
	US 2004072858	A1	20040415	US 2003-675833	20030930
	US 2004092545	A1	20040513	US 2003-696476	20031029
	US 2004097542	A1	20040520	US 2003-696478	20031029
PRAI	US 2000-254218P	P	20001208		
	US 2001-12599	A2	20011206		
	US 2001-11921	A1	20011206		
	US 2002-165443	A1	20020607		

OS MARPAT 139:133563
GI



I

AB Title compds. [I; X = CHR5, CHR5, CHR5, R1 = R4NR3SO2R6A, R4NR3SOR7, R4NR3SO2NR5R6A, R4NR3SO2NH2; A = alkyl, alkenyl, aryl, heteroaryl, heterocyclyl; R2 = H, (substituted) alkyl, alkenyl, aryl, heteroaryl,

heterocyclyl, alkyl-Y-alkyl, alkyl-Y-alkenyl, alkyl-Y-aryl; Y = O, S(O)0-2; R3 = H, alkyl, arylalkyl; R4 = alkyl, alkenyl, which may be interrupted by ≥1 O; R3R4 form a ring; R5 = H, alkyl, alkenyl; R6 = bond, alkyl, alkenyl, which may be interrupted by ≥1 O; R7 = alkyl; R3R7 form a ring; n = 0-4; R = alkyl, alkoxy, OH, halo, CF3], were prepared Thus, tert-Bu 2-[2-[(3-aminoquinolin-4-yl)amino]ethoxy]ethylcarbamate (preparation given) in CH2Cl2 was cooled to 0° and treated with Et3N and methoxypropionyl chloride; The reaction was then warmed to room temperature and stirring was continued for 1 h to give tert-Bu 2-[2-[2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethylcarbamate. This was converted to N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methanesulfonamide in several steps. I showed interferon induction in human cells with lowest effective concns. of 0.0001-1 μM.

IT **437382-50-8P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methanesulfonamide **437382-51-9P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]methanesulfonamide **437382-52-0P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methylmethanesulfonamide **437382-53-1P**, N-[2-[2-[4-Amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methylmethanesulfonamide **437382-55-3P 437382-56-4P 437382-58-6P 437382-61-1P 437382-75-7P 437382-76-8P 437382-78-0P 437382-89-3P 565454-55-9P 565454-56-0P 565454-57-1P 565454-58-2P 565454-59-3P 565454-60-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamidoalkoxyalkylimidazoquinolines as immune response modulators)

RN 437382-50-8 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-51-9 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-52-0 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 437382-53-1 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 437382-55-3 CAPLUS
CN Ethanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-56-4 CAPLUS
CN 2-Propanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-58-6 CAPLUS
CN 1-Butanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-61-1 CAPLUS
CN Benzenemethanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-75-7 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-7,7-dimethyl-2-oxo-, (1S,4R)-(9CI) (CA INDEX NAME)



PAGE 2-A



RN 437382-76-8 CAPLUS
CN Piperidine, 4-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]ethyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 437382-78-0 CAPLUS
CN Piperidine, 4-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]ethyl]-1-(butylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 437382-89-3 CAPLUS
CN 1-Butanesulfonamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 565454-55-9 CAPLUS
CN Methanesulfonamide, N-[2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 565454-56-0 CAPLUS
CN 2-Propanesulfonamide, N-[2-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 565454-57-1 CAPLUS
CN Methanesulfonamide, N-[2-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 565454-58-2 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 565454-59-3 CAPLUS
CN 2-Propanesulfonamide, N-[2-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 565454-60-6 CAPLUS
CN 2-Propanesulfonamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:449681 CAPLUS
DN 137:33297
TI Preparation of sulfonamido ether substituted imidazoquinolines as immune response modifiers
IN Crooks, Stephen L.; Greisgraber, George W.; Heppner, Philip D.; Merrill, Bryon A.; Roberts, Ralph R.; Wei, Ai-Ping
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046190	A2	20020613	WO 2001-US46582	20011206
	WO 2002046190	A3	20030717		
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002039517	A5	20020618	AU 2002-39517	20011206
	US 2003065005	A1	20030403	US 2001-11921	20011206
	US 6664260	B2	20031216		
	EP 1341790	A2	20030910	EP 2001-987283	20011206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300274	A	20031015	EE 2003-274	20011206
	JP 2004529078	T2	20040924	JP 2002-547927	20011206
	NO 2003002473	A	20030530	NO 2003-2473	20030530
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-11921	A1	20011206		
	WO 2001-US46582	W	20011206		

OS MARPAT 137:33297
GI



I

AB The title compds. [I; X = (CH2)2, (CH2)3, CHEtCH2, etc.; R1 = R4NR3SO2R6alkyl, R4NR3SO2R6aryl, etc.; R2 = H, alkyl, alkenyl, etc.; R3 = H, alkyl, aralkyl; R4 = alkylene or alkenylene interrupted by one or more O atoms; or R3R4 can join together to form a ring; R6 = a bond, alkylene or alkenylene which may be interrupted by one or more O atoms; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain substituted amine functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of I [X = (CH2)2; R1 = (CH2)2NMeSO2Me; R2 = (CH2)2OMe; n = 0] which showed the lowest concentration of 0.01 μM and 0.12 μM to induce interferon α and TNFα, resp., was given. The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT **437382-50-8P 437382-51-9P 437382-52-0P**
437382-53-1P 437382-55-3P 437382-56-4P
437382-58-6P 437382-61-1P 437382-75-7P
437382-76-8P 437382-78-0P 437382-89-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamido ether substituted imidazoquinolines as immune response modifiers)

RN 437382-50-8 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-51-9 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-52-0 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 437382-53-1 CAPLUS
CN Methanesulfonamide, N-[2-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 437382-55-3 CAPLUS
CN Ethanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-56-4 CAPLUS
CN 2-Propanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-58-6 CAPLUS
CN 1-Butanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-61-1 CAPLUS
CN Benzenemethanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 437382-75-7 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[2-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]-7,7-dimethyl-2-oxo-, (1S,4R)- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 437382-76-8 CAPLUS
CN Piperidine, 4-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]ethyl]-1-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 437382-78-0 CAPLUS
CN Piperidine, 4-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butoxy]ethyl]-1-(butylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 437382-89-3 CAPLUS
CN 1-Butanesulfonamide, N-[2-[2-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)ethoxy]ethyl]- (9CI) (CA INDEX NAME)



=>